Liquid biopsy of cancer: a multimodal diagnostic tool in clinical oncology DOI Creative Commons
Raffaele Palmirotta, Domenica Lovero, Paola Cafforio

и другие.

Therapeutic Advances in Medical Oncology, Год журнала: 2018, Номер 10

Опубликована: Янв. 1, 2018

Over the last decades, concept of precision medicine has dramatically renewed field medical oncology; introduction patient-tailored therapies significantly improved all measurable outcomes. Liquid biopsy is a revolutionary technique that opening previously unexpected perspectives. It consists detection and isolation circulating tumor cells, DNA exosomes, as source genomic proteomic information in patients with cancer. Many technical hurdles have been resolved thanks to newly developed techniques next-generation sequencing analyses, allowing broad application liquid wide range settings. Initially correlated prognosis, data are now being studied for cancer diagnosis, hopefully including screenings, most importantly prediction response or resistance given treatments. In particular, identification specific mutations target genes can aid therapeutic decisions, both appropriateness treatment advanced secondary resistance, aiming early diagnose disease progression. Still far from reality but ongoing research leading way new era oncology. This review summarizes main applications

Язык: Английский

A view on drug resistance in cancer DOI Open Access
Neil Vasan, José Baselga, David M. Hyman

и другие.

Nature, Год журнала: 2019, Номер 575(7782), С. 299 - 309

Опубликована: Ноя. 13, 2019

Язык: Английский

Процитировано

2103

Artificial intelligence in cancer imaging: Clinical challenges and applications DOI Open Access
Wenya Linda Bi, Ahmed Hosny, Matthew B. Schabath

и другие.

CA A Cancer Journal for Clinicians, Год журнала: 2019, Номер 69(2), С. 127 - 157

Опубликована: Фев. 5, 2019

Abstract Judgement, as one of the core tenets medicine, relies upon integration multilayered data with nuanced decision making. Cancer offers a unique context for medical decisions given not only its variegated forms evolution disease but also need to take into account individual condition patients, their ability receive treatment, and responses treatment. Challenges remain in accurate detection, characterization, monitoring cancers despite improved technologies. Radiographic assessment most commonly visual evaluations, interpretations which may be augmented by advanced computational analyses. In particular, artificial intelligence (AI) promises make great strides qualitative interpretation cancer imaging expert clinicians, including volumetric delineation tumors over time, extrapolation tumor genotype biological course from radiographic phenotype, prediction clinical outcome, impact treatment on adjacent organs. AI automate processes initial images shift workflow management whether or administer an intervention, subsequent observation yet envisioned paradigm. Here, authors review current state applied describe advances 4 types (lung, brain, breast, prostate) illustrate how common problems are being addressed. Although studies evaluating applications oncology date have been vigorously validated reproducibility generalizability, results do highlight increasingly concerted efforts pushing technology use future directions care.

Язык: Английский

Процитировано

1439

Tumor microenvironment complexity and therapeutic implications at a glance DOI Creative Commons
Roghayyeh Baghban, Leila Roshangar, Rana Jahanban-­Esfahlan

и другие.

Cell Communication and Signaling, Год журнала: 2020, Номер 18(1)

Опубликована: Апрель 7, 2020

Abstract The dynamic interactions of cancer cells with their microenvironment consisting stromal (cellular part) and extracellular matrix (ECM) components (non-cellular) is essential to stimulate the heterogeneity cell, clonal evolution increase multidrug resistance ending in cell progression metastasis. reciprocal cell-cell/ECM interaction tumor hijacking non-malignant force lose function acquire new phenotypes that promote development invasion cells. Understanding underlying cellular molecular mechanisms governing these can be used as a novel strategy indirectly disrupt interplay contribute efficient safe therapeutic strategies fight cancer. Furthermore, tumor-derived circulating materials also diagnostic tools precisely predict monitor outcome therapy. This review evaluates such potentials various advanced models, focus on 3D systems well lab-on-chip devices.

Язык: Английский

Процитировано

1413

Cholangiocarcinoma — evolving concepts and therapeutic strategies DOI
Sumera I. Ilyas, Shahid A. Khan, Christopher L. Hallemeier

и другие.

Nature Reviews Clinical Oncology, Год журнала: 2017, Номер 15(2), С. 95 - 111

Опубликована: Окт. 10, 2017

Язык: Английский

Процитировано

1367

Current and future perspectives of liquid biopsies in genomics-driven oncology DOI
Ellen Heitzer, Imran S. Haque,

Charles E. S. Roberts

и другие.

Nature Reviews Genetics, Год журнала: 2018, Номер 20(2), С. 71 - 88

Опубликована: Ноя. 8, 2018

Язык: Английский

Процитировано

1182

Genome-wide cell-free DNA fragmentation in patients with cancer DOI
Stephen Cristiano, Alessandro Leal, Jillian Phallen

и другие.

Nature, Год журнала: 2019, Номер 570(7761), С. 385 - 389

Опубликована: Май 29, 2019

Язык: Английский

Процитировано

1082

Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab DOI
David R. Gandara,

Sarah Paul,

Marcin Kowanetz

и другие.

Nature Medicine, Год журнала: 2018, Номер 24(9), С. 1441 - 1448

Опубликована: Июль 30, 2018

Язык: Английский

Процитировано

1045

Liquid biopsy enters the clinic — implementation issues and future challenges DOI
Michail Ignatiadis, George W. Sledge, Stefanie S. Jeffrey

и другие.

Nature Reviews Clinical Oncology, Год журнала: 2021, Номер 18(5), С. 297 - 312

Опубликована: Янв. 20, 2021

Язык: Английский

Процитировано

880

Enhanced detection of circulating tumor DNA by fragment size analysis DOI Open Access
Florent Moulière, Dineika Chandrananda, Anna Piskorz

и другие.

Science Translational Medicine, Год журнала: 2018, Номер 10(466)

Опубликована: Ноя. 7, 2018

Selective sequencing or in silico analysis for differences DNA fragment size can improve the detection of circulating tumor DNA.

Язык: Английский

Процитировано

864

Comprehensive human cell-type methylation atlas reveals origins of circulating cell-free DNA in health and disease DOI Creative Commons
Joshua Moss, Judith Magenheim,

Daniel Neiman

и другие.

Nature Communications, Год журнала: 2018, Номер 9(1)

Опубликована: Ноя. 23, 2018

Abstract Methylation patterns of circulating cell-free DNA (cfDNA) contain rich information about recent cell death events in the body. Here, we present an approach for unbiased determination tissue origins cfDNA, using a reference methylation atlas 25 human tissues and types. The method is validated silico simulations as well vitro mixes from different sources at known proportions. We show that plasma cfDNA healthy donors originates white blood cells (55%), erythrocyte progenitors (30%), vascular endothelial (10%) hepatocytes (1%). Deconvolution patients reveals contributions agree with clinical findings sepsis, islet transplantation, cancer colon, lung, breast prostate, unknown primary. propose procedure which can be easily adapted to study cellular contributors many settings, opening broad window into pathologic dynamics.

Язык: Английский

Процитировано

794